TRAUMA
AAOS: Quantitative ultrasound can detect the effects of risendronate on bone strength
138 women (100 at final follow-up) who underwent short proximal femoral nailing for a low-energy intertrochanteric fracture were randomized to receive either risendronate (75 mg twice monthly) or a placebo equivalent. The purpose of this study was to examine whether quantitative ultrasound was able to detect the effects of risendronate on bone strength, as confirmed by the incidence of re-fracture in these women. Results indicated that quantitative ultrasound was able to detect that bone strength increased in patients taking risendronate compared to placebo, as confirmed by the lower incidence of re-fracture in the risendronate group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
